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Abstract
T-cell Prolymphocytic leukemia (T-PLL) is a rare post-thymic T-cell malignancy that follows an aggressive clinical
course. The classical presentation includes an elevated white blood cell (WBC) count with anemia and
thrombocytopenia, hepatosplenomegaly, and lymphadenopathy. T-PLL is a disease of the elderly and to our
knowledge it has never been described in the pediatric age group. We report a case of T-PLL in a 9 year old male
who was initially diagnosed with T-cell acute lymphoblastic lymphoma (ALL), the diagnosis was later refined to
T-PLL following additional analysis of bone marrow morphology and immunophenotype. Two unusual findings in
our patient included CD117 expression and an isolated chromosomal 12(p13) deletion. The patient failed to
respond to standard ALL induction chemotherapy, but achieved complete remission following treatment with a
fludarabine and alemtuzumab-based regimen.
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Introduction
T-cell prolymphocytic leukemia (T-PLL) is an aggressive
lymphoproliferative disorder that represents approxi-
mately 2% of all mature lymphocytic leukemias in adults.
Most patients present with hepatosplenomegaly, lympha-
denopathy, and marked lymphocytosis. Less commonly
skin lesions and serous effusions develop. T-PLL is char-
acterized by proliferation of small to medium-sized pro-
lymphocytes with nongranular basophilic cytoplasm;
round, oval, or markedly irregular nuclei; and a promi-
nent nucleolus. In approximately 20% of cases a “small
cell variant” is seen. The immunophenotype of T-PLL
cells resembles that of a mature post-thymic T-cell with
expression of CD2, CD3, and CD7. The T-cell receptor
(TCR) beta/gamma genes are clonally rearranged. The
most frequent chromosomal abnormalities in T-PLL
include inversion of chromosome 14 with breakpoints in
the long arm of q11 and q32 and abnormalities of chro-
mosome 8 [1].
T-PLL arises sporadically in adults and is mainly a dis-
ease of the elderly with a median age at onset of 65 years
[2]. A mature T-cell malignancy with phenotypic and
genotypic features indistinguishable from T-PLL has
been described in patients with ataxia-telangiectasia [3].
In contrast to sporadic cases T-PLL, this entity is seen in
younger adults with a median age of onset of 31 years.
We present a case of a 9-year-old male diagnosed with
T-PLL based on morphology, immunophenotype, cytoge-
netic and molecular T-cell receptor studies of bone mar-
row. A thorough literature search through Medline,
Pubmed, and Google scholar did not reveal any previous
description of T-PLL presenting in the pediatric age
group. Because this patient showed no clinical or cytoge-
netic features of ataxia-telangiectasia, this is likely a case of
sporadic T-PLL, making it even more intriguing.
Case presentation
The patient is a 9-year-old African-American male with
no significant personal or family medical history who was
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well until about 2 months ago when he started having
intermittent fevers, nonbloody nonbilious vomiting, fati-
gue and abdominal pain. He completed 2 courses of anti-
biotics during that time. Three days prior to admission,
he went back to his pediatrician who started him on
another course of antibiotics. A CBC was done at that
time which revealed severe anemia. So he was sent to the
local community hospital emergency department. Physi-
cal examination revealed fever (temperature of 38.9°C),
periorbital edema, bilateral pitting pedal edema, hepato-
megaly (5 cm), splenomegaly (3 cm), and cervical and
axillary lymphadenopathy. A complete blood count
showed a hemoglobin of 4.4 g/dl, a white blood cell
count of 10.6 × 103/μl with 98% lymphocytes and 2%
blasts, and a platelet count of 119 × 103/μl. Blood bio-
chemical analysis revealed elevated LDH of 739 units/L
(reference range 94-250). Additional studies revealed
hypoalbuminemia (2.5 g/dl, reference range 3.5-4.8) and
increased hyperferritinemia (1,510 ng/mL, reference
range 22.0-322.0). Serology for HTLV-1 was negative
while CMV IgG was positive suggesting prior exposure.
Bone marrow aspiration was interpreted as T-ALL based
on morphology and cell surface marker expression as
detailed below.
Four-drug induction chemotherapy following COG
protocol AALL0434, consisting of intrathecal cytarabine
and systemic vincristine, prednisone, daunorubicin, and
PEG-asparaginase was started. Day 8 bone marrow aspi-
rate showed decrease in leukemic cells. Induction che-
motherapy was continued as planned. Bone marrow
aspiration done on day 15 of induction showed progres-
sive disease. The lack of response to standard T-ALL
induction chemotherapy prompted a revision of the diag-
nosis. Evaluation of the bone marrow specimens revealed
prolymphocytic appearing cells that lacked expression of
markers of immaturity such as CD34, TdT, and CD1a
even though there was expression of CD117. This unu-
sual immunophenotype, morphology and lack of clinical
response, resulted in a revision of the diagnosis to T-cell
prolymphocytic leukemia.
Following change in diagnosis and progressive disease
under standard induction chemotherapy, induction che-
motherapy was abandoned and the patient was started
on nelarabine as a single agent with intention to add
cyclophosphamide and cytarabine. Lack of evidence of
tumor lysis at the end of nelarabine therapy prompted a
repeat of bone marrow aspiration which showed persis-
tent disease. The child then was treated with another
regimen termed FLACC, which consisted of fludarabine,
cytarabine, cyclophosphamide, and alemtuzumab with fil-
gastrim (G-CSF) support and was described in detail by
Williams et al. [4], who used this regimen to successfully
treat a child with refractory T-cell post-transplant lym-
phoproliferative disorder (PTLD). The patient received
valacyclovir for prophylaxis against CMV reactivation
and pentamidine for PCP prophylaxis.
Upon hematopoietic recovery, bone marrow aspiration
and biopsy showed trilineage maturation with no evidence
of leukemia by morphology or flow cytometry confirming
remission status. The child had no biological siblings as
potential stem cell donor. While the search for a suitable
stem cell source was underway, the child received a sec-
ond course of the FLACC therapy to sustain remission sta-
tus. During neutropenic phase of this second cycle the
child developed respiratory distress with fevers. At the
time of neutrophil recovery, respiratory distress worsened
necessitating mechanical ventilation. This was followed by
failure of renal and hepatic systems. All blood cultures
remained negative for bacterial or fungal etiology. Bronch-
oalveolar lavage confirmed evidence of PCP as well as
CMV by PCR with no evidence of fungal elements. His
blood CMV viral titers were over 3.9 × 106 copies/ml. The
child succumbed to these complications in spite of aggres-
sive therapy including ganciclovir, trimethoprim sulfisoxa-
zole, pentamidine, broad spectrum antibacterial as well as
antifungal therapies. The family opted against postmortem
examination.
Pathologic findings
Morphologic analysis
The hemogram revealed anemia normal leukocyte count
(10.8 × 103/μl; reference range, 4.8-10.8 × 103/mL) with
neutropenia (ANC 648/μl reference range 1,500-7,600)
and lymphocytosis (94%; reference range, 20%-40%). The
Wright-stained peripheral blood smear revealed leukemic
cells having high N/C ratio, relatively dense chromatin
and occasional prominent nucleoli (Figure 1A). The
Wright-stained bone marrow aspirate smears showed a
population of small to medium sized lymphoid cells com-
prising all nucleated cells. These cells were similar in
morphology to those seen in the peripheral blood. The
hematoxylin-eosin-stained bone marrow biopsy was
highly cellular (90-95%) and displayed sheets of immature
lymphoid cells (Figure 1B and 1C)
Immunophenotypic analysis
Immunohistochemistry was performed on paraffin-
embedded sections of the bone marrow core biopsy. Anti-
bodies directed against CD3 and CD117 strongly reacted
to tumor cells (Figure 1D), and an antibody directed CD20
showed no reaction. The CD3 and CD20 antibodies were
purchased from Ventana Medical Systems® (Oro Valley,
AZ) and the CD117 antibody was purchased from Cell
Marque Corporation© (Rocklin, CA). Flow cytometric ana-
lysis was performed on bone marrow aspirate using a
FACSCalibur™ 2000 flow cytometer and monoclonal
antibodies purchased from Becton Dickinson (San Jose,
CA). Flow cytometry showed a marked expansion of
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T cells (95% of the total lymphocyte gate) that were mod-
erately positive for CD5, CD8, CD38, cytoplasmic CD3,
CD117, and strongly positive for CD45, CD7 and CD52.
The expanded T-cell population was negative for CD2,
surface CD3, surface TCR-alpha/beta, surface TCR-
gamma/delta, CD4, CD56, CD57, CD10, CD34, CD1a,
TdT, and CD135 (Figure 2).
Cytogenetic analysis
G-banded metaphase analysis and fluorescence in situ
hybridization (FISH) were performed on bone marrow
aspirate using standard cytogenetic techniques. Fourteen
trypsin-Giemsa banded metaphases from a 24 hour cul-
ture were analyzed revealing a normal male karyotype
(46, XY). FISH was performed with the CEP 4 (4p11-
q11), LSI BCR/ABL DC DF (9q34,22q11.2), CEP 10
(10p11-q11.1), LSI MLL DC BAR (11q23), LSI ATM
(11q22.3), CEP 11 (11p11.11-q11), LSI TEL/AML1 ES
(12p13/21q22), CEP 17 (17p11.1-q11.1 (D17Z1)), LSI
MYC DC BAR (8q24), LSI IGH DC BAR (14q32), CEP 8
(8p11.1 - q11.1(D8Z2)) and LSI TCR alpha/delta DC
BAR (14q11.2) probes, and analyzed on 200 interphase
nuclei per probe. All probes were purchased from Abbott
Molecular© (Des Plaines, IL). A deletion of 12 (p13) was
demonstrated in 97% of the nuclei analyzed (Figure 3).
All other probes displayed a normal signal pattern.
Molecular analysis
DNA was extracted from formalin-fixed, paraffin-
embedded (FFPE) tissue sections of bone marrow using
the QIAamp DNA FFPE Tissue kit (QIAGEN Inc., Valen-
cia, CA). Polymerase chain reaction (PCR) amplification
was performed using Techne Thermal Cycler TC3000
(Techne Inc. Burlington, NJ). The PCR reaction mix con-
tained Taq polymerase, MgCl2, and 10 × buffer (AmpliTaq
Gold, Roche Biochemicals, CA), dNTPs (GeneAmp®
dNTP MIX., Roche Biochemicals, CA) and primers for the
variable, V and joining, J regions of the TCR-G (T-cell
receptor gamma) chain. The amplification products were
subsequently analyzed by electrophoresis on a 3% Meta-
Phor agarose gel (Lonza Rockland, Inc., Rockland, ME). In
this analysis a discrete 170 bp band indicated the presence
of a monoclonal T-cell population as previously described
[5-7] (Figure 4).
Discussion of case and review of literature
T-PLL is a rare disease, representing approximately 2%
of all mature lymphocytic leukemias in adults [8] and
Figure 1 A, Peripheral blood smear showing a lymphoma cell with relatively condensed chromatin and prominent nucleolus. (Wright-
Giemsa, original magnification ×1000). B, Bone marrow core biopsy showing hypercellular marrow with complete replacement by a diffuse
lymphocytic infiltrate (Hematoxylin-Eosin, original magnification ×200). C, Bone marrow core biopsy showing large lymphocytes with relatively
condensed chromatin and occasional nucleoli (Hematoxylin-Eosin, original magnification ×400). D, CD117 immunohistochemistry of bone
marrow core biopsy showing strong membranous and cytoplasmic staining of tumor cells (original magnification ×200). Please refer to
subsection entitled “Morphologic Analysis” for further details.
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3% of T-cell malignancies overall [9]. T-PLL was initially
described in a patient who presented with clinical and
morphologic features similar to B-PLL, but in whom the
cells were shown to be E-rosette positive, indicating a
T-cell phenotype [10]. Following a series of studies by
Matutes and coworkers between 1986 and 1991, T-PLL
became established as a distinct T-cell malignancy
[8,11,12].
Figure 2 Flow cytometry dot plots showing lymphoma cells positive for cytoplasmic CD3 (cCD3), CD8, CD117, CD7, CD52, and
negative for surface CD3, CD4, TCR alpha/beta, TdT, CD34, and CD135. Please refer to subsection entitled “Immunophenotypic Analysis” for
further details.
Figure 3 Interphase FISH using the LSI TEL/AML1 ES (12p13 green/21q22 orange) probe, showing a normal signal pattern of two
orange and two green (2O2G) on the left and the abnormal signal pattern of two orange and one green (2O1G) on the right,
indicating a deletion of 12(p13). Please refer to subsection entitled “Cytogenetic Analysis” for further details.
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The most common symptoms at presentation are
splenomegaly (73%), followed by lymphadenopathy
(53%), hepatomegaly (40%), and cutaneous lesions such
as maculopapular rash and focal erythroderma (27%).
Serous effusions, predominantly pleural and pericardial,
are present in about 15% of patients at presentation and
in up to 37% of patients later in the course of the dis-
ease [13]. Seventy-five percent of these patients had an
elevated white blood cell count (typically > 100 k/mcl)
at presentation. T-PLL has a distinctively short prodro-
mal period, with about 63% of patients reporting leuke-
mia-related symptoms for a median of two months prior
to diagnosis. This is in contrast with other mature T-cell
malignancies such as Sézary Syndrome and T-LGL,
which have prodromes with a medium duration of 24-
38 months and 9 months, respectively [13].
Marked morphologic heterogeneity has been observed
in cases of T-PLL. Over three quarters of cases show typi-
cal prolymphocyte morphology that may be indistinguish-
able from that of B-PLL, namely medium sized lymphoid
cells with moderately condensed nuclear chromatin and
prominent central nucleoli. T-prolymphocytes tend to
have more intense cytoplasmic basophilia and nuclear irre-
gularity than B-prolymphocytes. In some cases, cytoplas-
mic protrusions or blebs may be present. In about 20% of
T-PLL cases, the cells are smaller with more condensed
nuclear chromatin and inconspicuous nucleoli. Such cases
were originally referred to as T-CLL, but now are classified
as the small cell variant of T-PLL. Less commonly, in
about 5% of cases, the cells show markedly irregular nuclei
resembling those seen in Sézary cells. While originally
labeled as Sézary cell leukemia, these cases are now desig-
nated as the cerebriform variant of T-PLL. Both variants
were reclassified because they shared the same immuno-
phenotypic and cytogenetic features as typical cases of
T-PLL [14].
The immunophenotype of T-prolymphocytes is con-
sistent with that of a mature post-thymic T-cell. They
are negative for CD1a and TdT, but positive for pan
T-cell markers such as CD2, CD3, CD5, and CD7. CD7
is expressed with stronger intensity than seen in normal
T-cells and other mature T-cell malignancies, but at
levels comparable to those seen in T-ALL [15]. Surface
expression of CD3 and TCR-a/b may not be detected in
up to 20% of cases, but their expression is always seen
in the cytoplasm [15]. While most cases (65%) consist of
CD4+/CD8- cells, 21% of cases are CD4+/CD8+ and
13% of cases are CD4-/CD8+ [8]. There is variable
expression of antigens related to T-cell activation, such
as CD25, CD38, and HLA-DR. While not a lymphocyte
specific marker, CD52 is more strongly expressed in
T-prolymphocytes than in normal T-cells [16].
While the immunophenotype of our case is predomi-
nantly that of a mature T-cell malignancy, the expression
of CD117 (c-kit) seems counterintuitive. CD117 is nor-
mally expressed by a subset of thymocytes during normal
lymphopoiesis which have not yet undergone rearrange-
ment of their T-cell receptor (TCR) genes [17], playing a
vital role in early T-cell development. This marker is also
normally expressed by hematopoietic progenitor cells of
all lineages [17]. Therefore CD117 serves as a surrogate
marker of immaturity, with expression in a subset of pre-
cursor T-cell lymphoblastic neoplasms [18,19]. A review
of the literature for the incidence of CD117 expression in
mature T-cell malignancies showed CD117 expression
restricted to CD4-/CD8+ cases [20], consistent with the
present case.
Many cytogenetic studies have identified several recur-
rent chromosomal abnormalities in T-PLL. Up to 90% of
patients have abnormalities of chromosome 14 that can
be demonstrated by FISH. The majority of these abnorm-
alities consist of either inv(14)(q11q32) or t(14;14)(q11;
q32) [1]. Inv(14)(q11q32) alone can be detected by con-
ventional cytogenetic studies in more than two-thirds of
cases [21]. About 19% of patients have karyotypes show-
ing abnormalities of Xq28, the most common of which is
t(X;14)(q28;q11) [1]. Such rearrangements are now con-
sidered to be a genetic hallmark of T-PLL and a primary
event in its oncogenesis. Both inv(14)(q11q32) or t(14;14)
Figure 4 Clonality analysis of T-cell receptor gamma chain
gene by PCR showing a discrete band indicative of a
monoclonal rearrangement. Lane 1, positive control. Lane 2,
normal control. Lane 3 and 4, patient sample. Lane 5, blank. MW,
molecular weight marker. Please refer to subsection entitled
“Molecular Analysis” for further details.
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(q11;q32) result in the overexpression of the TCL1 onco-
gene located on 14q32.1 through its juxtaposition to the
TCR-alpha gene on 14q11. When overexpressed, the
TCL1 protein binds the D3 phosphoinositide-regulated
kinase AKT1 in the cytoplasm, augmenting its transport
into the nucleus. This results in increased expression of
genes responsible for promoting T-cell proliferation and
survival [22]. Likewise, t(X;14)(q28;q11) juxtaposes the
MCTP1 (mature T-cell proliferation 1) gene to TCR-
alpha gene. MCTP1 is a homologue of TCL1 that also
binds to AKT1 [23,24]. Interestingly, inv(14)(q11q32),
t(14;14)(q11;q32), and t(X;14)(q28;q11) have all been
detected in expanding T-cell clones from patients with
ataxia-telangiectasia. Such clones are usually subclinical
and identified as incidental findings several years before
lymphoma develops [3].
Besides the aberrations on chromosome 14, most T-
PLL cells usually harbor other secondary chromosomal
abnormalities. Unbalanced rearrangements of chromo-
some 8 are the most common secondary abnormalities
and have been reported in up to 80% of cases. Such
chromosome 8 abnormalities include trisomy 8q, iso-
chromosome 8(q10), t(8;8)(p12;q11), and translocations
with other chromosomes [25]. In addition, c-myc pro-
tein amplification has been demonstrated by flow cyto-
metry [26]. Despite their high frequency, the role of
these chromosome 8 abnormalities in the pathogenesis
of T-PLL remains to be elucidated.
Although conventional cytogenetics revealed a normal
karyotype, a comprehensive panel of FISH probes detected
an isolated deletion of the (p13) region of chromosome
12. As a result of limited resolution, this deletion cannot
be visualized using standard cytogenetic techniques (i.e.
karyotyping) and requires FISH for detection. It is present
in nearly half of T-PLL cases [27], but has always been
accompanied by the well characterized aberrations of
either chromosomes 14, X, or 8 [1,12,28,29]. Considering
that abnormalities of 14q11 [i.e. t(14;14)(q11;q32), inv(14)
(q11q32), t(X;14)(q28;q11)] and chromosome 8 [i.e. i(8)
(q10), t(8;8)(p12;q11)] are each present in up to 90% and
80% of T-PLL patients, respectively [1,23], we believe that
the present case is the first report of a patient with an iso-
lated deletion of the 12(p13) region. A review of the litera-
ture for T-PLL cases lacking the common abnormalities of
chromosomes 14, X, and 8 showed an overrepresentation
of CD4-/CD8+ T-PLL cases like ours [12,30]. Therefore
our case may represent a subset of T-PLL cases in which
alternative pathways are likely responsible for its patho-
genesis. The minimal region of 12(p13) deletion contains
the CDKN1B gene, which encodes the cell cycle regulatory
protein p27KIP1 [27,31]. Decreased expression of this pro-
tein results in stabilization of cyclinD-CDK4/6 complexes
and facilitates cell cycle progression [32], which was
shown to be sufficient for the development of T-PLL in
mouse models [31].
The most important differential diagnosis in the pedia-
tric age group is T-ALL. T-ALL typically presents as a
mediastinal mass with an immunophenotype consistent
with late cortical thymocytes (i.e. positive for TdT, CD1a,
cytoplasmic CD3, CD4, and CD8). T-ALL cells may range
from small, round cells with high N/C ratios, relatively
condensed chromatin and inconspicuous nucleoli to larger
cells with abundant basophilic cytoplasm, irregular nuclear
contour, dispersed chromatin and one or more distinct
nucleoli [14]. It is this cytologic heterogeneity that may
pose a challenge in differentiating T-ALL from T-PLL in a
child, since it may overlap with the T-PLL cytologic spec-
trum. Furthermore, as previously mentioned, rare cases of
T-PLL will aberrantly express CD117, a marker more
commonly seen in up to 11% of T-ALL cases. Importantly,
T-ALL cases that express CD117 also carry activating
mutations of the FLT3 receptor tyrosine kinase (i.e.,
CD135), the genetic abnormality most commonly seen in
AML [18]. In contrast, our case did not express CD135 by
flow cytometry and no mutations were detected by PCR
(data not shown), arguing against a diagnosis of T-ALL.
The WHO categorizes T-cell and NK-cell neoplasms
into broad clinically defined groups such as leukemic or
disseminated, nodal, extranodal, and cutaneous [14]. The
most common mature T-cell malignancy in children is
anaplastic lymphoma kinase (ALK) positive anaplastic
large cell lymphoma (ALCL), account for up to 30% of
lymphomas in the pediatric age group. It has been sug-
gested that a majority of non-ALCL T-cell/NL-cell lym-
phomas in children tend to be derived from components
of the innate immune system such as cytotoxic T or NK
cells [33]. Consistent with this, CD4-/CD8+ T-cell lym-
phomas were observed in young transgenic mice models
of T-PLL [34]. Therefore it appears that evolutionary pri-
mitive components of the immune system are featured
more often in pediatric hematologic malignant neoplasms,
and conversely tumors of the adaptive immune system, a
more mature component of the immune system, are
exceptionally rare in children [33]. The frequency of non-
anaplastic mature T-cell lymphomas in children is too low
for performing large scale clinical trials. Therefore not
much is known about their prognosis and optimal choice
of therapy.
Standard T-cell ALL induction therapy was not effec-
tive in this case. FLACC regimen was effective in achiev-
ing remission status while definitive therapy is most
likely with stem cell transplantation. This case illustrates
that the diagnosis of T-PLL should be entertained in all
children with T-ALL and alternative induction regimens
such as the one used in this case should be entertained
early in the course of treatment.
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FLACC regimen is highly immunosuppressive. Reacti-
vation of CMV should be considered in all cases where
evidence of prior CMV exposure is present. This may
happen in spite of standard prophylactic use of valacy-
clovir, and periodic monitoring of peripheral blood
CMV viral load may be appropriate. Those children
with no evidence of prior CMV exposure should receive
CMV-negative blood products and screened periodically
for new exposure. Similarly, although pentamidine was
used to prevent PCP pneumonitis, it was ineffective in
this case. Trimethoprim/sulfisoxazole, although may
lead to prolonged neutropenia, may be more effective
and should be considered.
To our knowledge, the present case is the first report of
T-PLL in a child. The lack of underlying ataxia-telangiec-
tasia makes this a case of sporadic T-PLL, which is even
more intriguing. While T-ALL is the more commonly
seen T-cell malignancy in the pediatric age group, this
case highlights the importance of keeping mature T-cell
malignancies in the differential diagnosis. Furthermore,
the regimen successfully used in this case may provide a
valuable option for clinicians attempting to treat rare cases
of pediatric mature T-cell malignancies. The isolated dele-
tion 12(p13) in our case highlights the importance of alter-
native mechanisms of T-PLL leukemogenesis that needs to
be further investigated. Finally, additional studies are
necessary to determine the prognostic significance of
CD117 expression in mature T-cell malignancies and its
restriction to CD4-/CD8+ cases.
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